Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.20 (
alpha-glucosidase
)
4,237
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present studies were undertaken to investigate the possible mechanism(s) of action of 2,2-dimethyl-1-(4-methylphenyl)-1-propanone (SaH 50-283) on food efficiency in rats. SaH 50-283, unlike phenformin (
DBI
), did not inhibit glucose absorption. However, hyperglycemia induced by oral maltose, lactose or starch load was markedly inhibited in animals pretreated with SaH 50-283. The ED25 for lowering blood sugar levels following an oral maltose load was calculated to be 12 mg/kg. SaH 50-283 could be administered as long as 7 hr prior to a maltose load and still maintain its effect. Food efficiency was significantly (P less than .01) lowered in rats pretreated with SaH 50-283 1 hr prior to a 2 hr feeding period of a purified high carbohydrate diet. It was concluded that the lowering of
maltase
activity in the brush border of animals treated with SaH 50-283 could partially account for its mechanism of action in lowering food efficiency in rats.
...
PMID:The influence of 2,2-dimethyl-1-(4-methylphenyl)-1-propanone (SaH 50-283) on food efficiency in rats. 48 87